News NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Delayed Canadian Securities Exchange Other stock markets 09:32:27 2024-04-30 am EDT			5-day change	1st Jan Change
0.3 ^CAD	-.--%		-.--%	-14.29%

Apr. 10	Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	CI
Apr. 04	NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS	Apr. 10	AQ
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	Apr. 10	CI
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS	Apr. 05	AQ
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD	Apr. 04	AQ
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	Apr. 04	CI
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS	Apr. 02	AQ
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE	Mar. 12	AQ
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	Mar. 12	CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	Mar. 11	MT
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING	Mar. 11	AQ
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	Mar. 11	CI
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024	Feb. 29	AQ
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	Feb. 27	CI
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	Feb. 27	AQ
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 26	CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients	Feb. 26	CI
NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS	Feb. 26	AQ
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials	Feb. 15	CI
NETRAMARK TO PRESENT NEW DATA DEMONSTRATING THE POWER OF ITS AI BASED TECHNOLOGY TO DE-RISK NEUROLOGY CLINICAL TRIALS AT ISCTM ANNUAL MEETING	Feb. 15	AQ
NETRAMARK ANNOUNCES LAUNCH OF THE NETRA AI LAB	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Summary

Filters